Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Cingulate to Present at 13th Annual LD Micro Invitational

May 25, 2023 at 15:55 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

KANSAS CITY, Kan., May 25, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it will participate in the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, Los Angeles, California, on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private one-on-one meetings.

Cingulate Chairman & CEO Shane J. Schaffer is scheduled to present a company overview on June 6th at 9:30 a.m. PST. A webcast of the presentation will be available on the investors section of Cingulate’s corporate site at www.cingulate.com.

Cingulate’s lead Phase 3 candidate, CTx-1301, is a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivity disorder (ADHD). In addition to the Company’s initial focus on the $22bn ADHD market, Cingulate is identifying other indications, such as anxiety, where it’s PTR™ technology may be effectively utilized.

To arrange a meeting with Cingulate, please contact your LD Micro representative, or Cingulate investor relations at mkreps@darrowir.com.

About Cingulate®
Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company utilizing its proprietary PTR™ drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of neurological disorders, Cingulate is identifying and evaluating additional therapeutic areas where PTR™ technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information visit Cingulate.com.

Investor Contact:
Thomas Dalton
Vice President, Investor & Public Relations, Cingulate
913-942-2301
TDalton@cingulate.com

Matt Kreps
Darrow Associates Investor Relations
214-597-8200
mkreps@darrowir.com